3SBio Acquires Global Rights to Apexigen RA Drug

China's 3SBio obtained global rights to an anti-TNF mAb for autoimmune disease, including rheumatoid arthritis, which was discovered by Apexigen of the San Francisco area. 3SBio in-licensed China rights to SSS07 in 2006; the new pact extends that agreement to include the rest of the world. 3SBio started a China Phase I trial of the molecule earlier this year. The ex-China rights will allow 3SBio to bring the drug to the lucrative US and European markets. No financial details were disclosed. More details.... Stock Symbol: (HKEX: 1530) Share this with colleagues: // //